1
|
Schurr T, Loth F, Lidington E, Piccinin C, Arraras JI, Groenvold M, Holzner B, van Leeuwen M, Petersen MA, Schmidt H, Young T, Giesinger JM. Patient-reported outcome measures for physical function in cancer patients: content comparison of the EORTC CAT Core, EORTC QLQ-C30, SF-36, FACT-G, and PROMIS measures using the International Classification of Functioning, Disability and Health. BMC Med Res Methodol 2023; 23:21. [PMID: 36681808 PMCID: PMC9862545 DOI: 10.1186/s12874-022-01826-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2022] [Accepted: 12/20/2022] [Indexed: 01/22/2023] Open
Abstract
BACKGROUND Patient-reported physical function (PF) is a key endpoint in cancer clinical trials. Using complex statistical methods, common metrics have been developed to compare scores from different patient-reported outcome (PRO) measures, but such methods do not account for possible differences in questionnaire content. Therefore, the aim of our study was a content comparison of frequently used PRO measures for PF in cancer patients. METHODS Relying on the framework of the International Classification of Functioning, Disability and Health (ICF) we categorized the item content of the physical domains of the following measures: EORTC CAT Core, EORTC QLQ-C30, SF-36, PROMIS Cancer Item Bank for Physical Function, PROMIS Short Form for Physical Function 20a, and the FACT-G. Item content was linked to ICF categories by two independent reviewers. RESULTS The 118 items investigated were assigned to 3 components ('d - Activities and Participation', 'b - Body Functions', and 'e - Environmental Factors') and 11 first-level ICF categories. All PF items of the EORTC measures but one were assigned to the first-level ICF categories 'd4 - Mobility' and 'd5 - Self-care', all within the component 'd - Activities and Participation'. The SF-36 additionally included item content related to 'd9 - Community, social and civic life' and the PROMIS Short Form for Physical Function 20a also included content related to 'd6 - domestic life'. The PROMIS Cancer Item Bank (v1.1) covered, in addition, two first-level categories within the component 'b - Body Functions'. The FACT-G Physical Well-being scale was found to be the most diverse scale with item content partly not covered by the ICF framework. DISCUSSION Our results provide information about conceptual differences between common PRO measures for the assessment of PF in cancer patients. Our results complement quantitative information on psychometric characteristics of these measures and provide a better understanding of the possibilities of establishing common metrics.
Collapse
Affiliation(s)
- T Schurr
- Department of Psychiatry, Psychotherapy, Psychosomatics, and Medical Psychology, University Hospital of Psychiatry I, Innsbruck Medical University, Anichstraße 35, A-6020 Innsbruck, Austria
| | - F Loth
- Professorship for Psychological Diagnostics and Intervention Psychology, Faculty of Philosophy and Education, Catholic University of Eichstätt-Ingolstadt, Ostenstraße 25, 85072 Eichstätt, Germany
| | - E Lidington
- Cancer Behavioural Science Unit, King’s College London, Guy’s Hospital, St Thomas Street, London, SE1 9RT UK
| | - C Piccinin
- Quality of Life Department, EORTC, Avenue E. Mounier, 83/11, 1200 Brussels, Belgium
| | - JI Arraras
- Medical Oncology Department, Hospital Universitario de Navarra, C/Irunlarrea 3, S31008 Pamplona, Spain
| | - M Groenvold
- Palliative Care Research Unit, Department of Geriatrics and Palliative Medicine GP, Bispebjerg & Frederiksberg Hospital, University of Copenhagen, Copenhagen, Denmark
| | - B Holzner
- Department of Psychiatry, Psychotherapy, Psychosomatics, and Medical Psychology, University Hospital of Psychiatry II, Innsbruck Medical University, Anichstraße 35, A-6020 Innsbruck, Austria
| | - M van Leeuwen
- Division of Psychosocial Research & Epidemiology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
| | - MA Petersen
- Palliative Care Research Unit, Department of Geriatrics and Palliative Medicine GP, Bispebjerg & Frederiksberg Hospital, University of Copenhagen, Copenhagen, Denmark
| | - H Schmidt
- University Clinic and Outpatient Clinic for Radiotherapy and Institute of Health and Nursing Science, Medical Faculty of Martin Luther University Halle-Wittenberg, Halle (Saale), Germany
| | - T Young
- Lynda Jackson Macmillan Centre, Mount Vernon Cancer Centre, Rickmansworth Rd, GB- HA6 2RN Halle (Saale), UK
| | - JM Giesinger
- Department of Psychiatry, Psychotherapy, Psychosomatics, and Medical Psychology, University Hospital of Psychiatry II, Innsbruck Medical University, Anichstraße 35, A-6020 Innsbruck, Austria
| |
Collapse
|
2
|
Bjelic-Radisic V, Cardoso F, Cameron D, Brain E, Kuljanic K, da Costa RA, Conroy T, Inwald EC, Serpentini S, Pinto M, Weis J, Morag O, Lindviksmoen Astrup G, Tomaszewski KA, Pogoda K, Sinai P, Sprangers M, Aaronson N, Velikova G, Greimel E, Arraras J, Bottomley A. Corrigendum to An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients: EORTC QLQ-BR45: Ann Oncol 2020; Volume 31, Issue 2, Pages 283-288. Ann Oncol 2020; 31:552. [PMID: 32089397 DOI: 10.1016/j.annonc.2020.02.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
Affiliation(s)
- V Bjelic-Radisic
- Breast Unit, Helios University Clinic, University Witten/Herdecke, Wuppertal, Germany.
| | - F Cardoso
- Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal
| | - D Cameron
- Cancer Research UK Edinburgh Centre, University of Edinburgh, Edinburgh, UK
| | - E Brain
- Department of Medical Oncology Institute Curie - Hôpital René Huguenin, Saint-Cloud, France
| | - K Kuljanic
- Department of Obstetrics and Gynecology, Clinical Center Rijeka, Rijeka, Croatia
| | - R A da Costa
- Department of Mastology and Breast Reconstruction, Barretos Cancer Hospital, Barretos, Brazil
| | - T Conroy
- Department of Medical Oncology, Lorraine Cancer Institute, Vandoeuvre-lès-Nancy, France
| | - E C Inwald
- Department of Gynecology and Obstetrics, University Medical Center Regensburg, Regensburg, Germany
| | - S Serpentini
- Unit for Psychooncology, Veneto Institute of Oncology IOVeIRCCS, Padua, Italy
| | - M Pinto
- National Tumor Institute, Instituto Nazionale Tumori Fondazione Pascale Naples, Naples, Italy
| | - J Weis
- Comprehensive Cancer Center, Medical Faculty, University Medical Center Freiburg, Freiburg, Germany
| | - O Morag
- Unit Pain Clinic, ShebaeTel Ha Shomer Hospital, Tel Aviv, Israel
| | | | - K A Tomaszewski
- Faculty of Medicine and Health Sciences, Andrzej Frycz Modrzewski Krakow University, Krakow, Poland
| | - K Pogoda
- Department of Breast Cancer and Reconstructive Surgery, Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland
| | - P Sinai
- Southmead Hospital, University of Bristol, Bristol, UK
| | - M Sprangers
- Department of Medical Psychology, Academic Medical Center, University of Amsterdam, Amsterdam
| | - N Aaronson
- Department of Psychosocial Research, NKI Netherlands, Amsterdam, The Netherlands
| | - G Velikova
- LeedsInstitute of Medical Research at St. James's, University of Leeds, Leeds, UK
| | - E Greimel
- Department of Gynecology and Obstetrics, Medical University Graz, Graz, Austria
| | - J Arraras
- Oncology Department, Hospital of Navarre, Pamplona, Spain
| | - A Bottomley
- EORTC HQ, Quality of Life Department, Brussels, Belgium
| | | |
Collapse
|
3
|
Bjelic-Radisic V, Cardoso F, Cameron D, Brain E, Kuljanic K, da Costa RA, Conroy T, Inwald EC, Serpentini S, Pinto M, Weis J, Morag O, Lindviksmoen Astrup G, Tomaszweksi KA, Pogoda K, Sinai P, Sprangers M, Aaronson N, Velikova G, Greimel E, Arraras J, Bottomley A. An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients: EORTC QLQ-BR45. Ann Oncol 2019; 31:283-288. [PMID: 31959345 DOI: 10.1016/j.annonc.2019.10.027] [Citation(s) in RCA: 44] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2019] [Revised: 10/25/2019] [Accepted: 10/28/2019] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND The European Organization for Research and Treatment of Cancer (EORTC) QLQ-BR23 was one of the first disease-specific questionnaires developed in 1996 to assess quality of life (QoL) in patients with breast cancer (BC). However, since 1996 major changes in BC treatment have occurred, requiring an update of the EORTC BC module. This study presents the results of the phase I-III update of the QLQ-BR23 questionnaire. PATIENTS AND METHODS The update of the EORTC QLQ-BR23 module followed standard EORTC guidelines. A systematic literature review revealed 83 potential relevant QoL issues during phases I and II. After shortening the issues list and following interviews with patients and health care providers, 15 relevant issues were transformed into 27 items. The preliminary module was pretested in an international, multicentre phase III study to identify and solve potential problems with wording comprehensibility and acceptability of the items. Descriptive statistics are provided. Analyses were qualitative and quantitative. We provide a psychometric structure of the items. RESULTS The phase I and II results indicated the need to supplement the original QLQ-BR23 with additional items related to newer therapeutic options. The phase III study recruited a total of 250 patients (from 12 countries). The final updated phase III module contains a total of 45 items: 23 items from the QLQ-BR23 and 22 new items. The new items contain two multi-item scales: a target symptom scale and a satisfaction scale. The target symptom scale can be divided into three subscales: endocrine therapy, endocrine sexual and skin/mucosa scale. CONCLUSION Our work has led to the development of a new EORTC QLQ-BR45 module that provides a more accurate and comprehensive assessment of the impact of new and scalable treatments on patients' QoL. The final version of the EORTC QLQ-BR45 is currently available for use in clinical practice. The final phase IV study is underway to confirm psychometric properties of the module.
Collapse
Affiliation(s)
- V Bjelic-Radisic
- Breast Unit, Helios University Clinic, University Witten/Herdecke, Wuppertal, Germany.
| | - F Cardoso
- Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal
| | - D Cameron
- Cancer Research UK Edinburgh Centre, University of Edinburgh, Edinburgh, UK
| | - E Brain
- Department of Medical Oncology Institute Curie - Hôpital René Huguenin, Saint-Cloud, France
| | - K Kuljanic
- Department of Obstetrics and Gynecology, Clinical Center Rijeka, Rijeka, Croatia
| | - R A da Costa
- Department of Mastology and Breast Reconstruction, Barretos Cancer Hospital, Barretos, Brazil
| | - T Conroy
- Department of Medical Oncology, Lorraine Cancer Institute, Vandoeuvre-lès-Nancy, France
| | - E C Inwald
- Department of Gynecology and Obstetrics, University Medical Center Regensburg, Regensburg, Germany
| | - S Serpentini
- Unit for Psychooncology, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy
| | - M Pinto
- National Tumor Institute, Instituto Nazionale Tumori Fondazione Pascale Naples, Naples, Italy
| | - J Weis
- Comprehensive Cancer Center, Medical Faculty, University Medical Center Freiburg, Freiburg, Germany
| | - O Morag
- Unit Pain Clinic, Sheba - Tel Ha Shomer Hospital, Tel Aviv, Israel
| | | | - K A Tomaszweksi
- Department of Surgery, Jagillonian University Medical College Krakow, Krakow, Poland
| | - K Pogoda
- Department of Breast Cancer and Reconstructive Surgery, Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland
| | - P Sinai
- Southmead Hospital, University of Bristol, Bristol, UK
| | - M Sprangers
- Department of Medical Psychology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
| | - N Aaronson
- Department of Psychosocial Research, NKI Netherlands, Amsterdam, The Netherlands
| | - G Velikova
- Leeds Institute of Medical Research at St. James's, University of Leeds, Leeds, UK
| | - E Greimel
- Department of Gynecology and Obstetrics, Medical University Graz, Graz, Austria
| | - J Arraras
- Oncology Department, Hospital of Navarre, Pamplona, Spain
| | - A Bottomley
- EORTC HQ, Quality of Life Department, Brussels, Belgium
| |
Collapse
|
4
|
Arraras JI, Illarramendi JJ, Manterola A, Asin G, Salgado E, Arrondo P, Dominguez MA, Arrazubi V, Martinez E, Viudez A, de la Cruz S, Vera R. Quality of life in elderly breast cancer patients with localized disease receiving endocrine treatment: a prospective study. Clin Transl Oncol 2019; 21:1231-1239. [PMID: 30712234 DOI: 10.1007/s12094-019-02048-4] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2018] [Accepted: 01/16/2019] [Indexed: 11/25/2022]
Abstract
PURPOSE In this paper we study the quality of life (QoL) of elderly breast cancer patients receiving endocrine treatment (ET). More QoL data on elderly patients treated with ET are needed. Our aims are to study QoL in early-stage breast cancer patients throughout the treatment period and compare the QoL of ET groups. METHODS 148 patients > 65 years who began ET with either tamoxifen or aromatase inhibitor (AI) completed the EORTC QLQ-C30 and QLQ-BR23 and the Interview for Deterioration in Daily Living Activities in Dementia (IDDD) questionnaires three times over 3 years of ET. Linear mixed-effect models were used to evaluate longitudinal QoL changes. ET group comparisons were conducted after 3 years of treatment via ANCOVA adjusted by basal QoL. RESULTS QoL scores were high (> 80/100 points) in most QoL areas, with moderate limitations (> 30) in sexual functioning and enjoyment and in future perspective. After 3 years of ET, four QoL areas improved (< 6 points) compared to baseline and 3-month assessments. Hot flushes worsened (8 points) at the 3-month assessment but by 3 years had recovered. AI patients showed more hot flushes, pain and diarrhea and less sexual enjoyment than tamoxifen patients after 3 years of ET (differences 3-12 points). CONCLUSIONS Results indicate that elderly early-stage breast cancer patients adapted well to their disease and ET treatment over the 3 years. Few QoL differences were observed between ET groups.
Collapse
Affiliation(s)
- J I Arraras
- Medical Oncology Department, Complejo Hospitalario de Navarra, Irunlarrea 3, 31008, Pamplona, Spain. .,Radiotherapeutic Oncology Department, Complejo Hospitalario de Navarra, Irunlarrea 3, 31008, Pamplona, Spain.
| | - J J Illarramendi
- Medical Oncology Department, Complejo Hospitalario de Navarra, Irunlarrea 3, 31008, Pamplona, Spain
| | - A Manterola
- Radiotherapeutic Oncology Department, Complejo Hospitalario de Navarra, Irunlarrea 3, 31008, Pamplona, Spain
| | - G Asin
- Radiotherapeutic Oncology Department, Complejo Hospitalario de Navarra, Irunlarrea 3, 31008, Pamplona, Spain
| | - E Salgado
- Medical Oncology Department, Complejo Hospitalario de Navarra, Irunlarrea 3, 31008, Pamplona, Spain
| | - P Arrondo
- Medical Oncology Department, Complejo Hospitalario de Navarra, Irunlarrea 3, 31008, Pamplona, Spain.,Radiotherapeutic Oncology Department, Complejo Hospitalario de Navarra, Irunlarrea 3, 31008, Pamplona, Spain
| | - M A Dominguez
- Radiotherapeutic Oncology Department, Complejo Hospitalario de Navarra, Irunlarrea 3, 31008, Pamplona, Spain
| | - V Arrazubi
- Medical Oncology Department, Complejo Hospitalario de Navarra, Irunlarrea 3, 31008, Pamplona, Spain
| | - E Martinez
- Radiotherapeutic Oncology Department, Complejo Hospitalario de Navarra, Irunlarrea 3, 31008, Pamplona, Spain
| | - A Viudez
- Medical Oncology Department, Complejo Hospitalario de Navarra, Irunlarrea 3, 31008, Pamplona, Spain
| | - S de la Cruz
- Medical Oncology Department, Complejo Hospitalario de Navarra, Irunlarrea 3, 31008, Pamplona, Spain
| | - R Vera
- Medical Oncology Department, Complejo Hospitalario de Navarra, Irunlarrea 3, 31008, Pamplona, Spain
| |
Collapse
|
5
|
Koch M, Jensen Hjermstad M, Tomaszewski K, Tomaszewska I, Hornslien K, Harle A, Arraras J, Morag O, Pompili C, Ioannidis G, Georgu M, Navarra C, Chie W, Johnson C, Himpel A, Schulz C, Bohrer T, Janssens A, Kulis D, Bottomley A, Koller M. Gender Aspekte in der Lebensqualität von Lungenkarzinom Patienten. Pneumologie 2018. [DOI: 10.1055/s-0037-1619214] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Affiliation(s)
- M Koch
- Med. Klinik und Poliklinik II, Klinikum der Universität Regensburg
| | - M Jensen Hjermstad
- Department of Cancer Research and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology, European Palliative Care Research Centre,
| | | | - I Tomaszewska
- Department of Medical Education, Uniwersytet Jagiellonski Collegium Medicum Wydzial, Lekarski
| | | | - A Harle
- Oncology, Poole Hospital NHS Foundation Trust
| | - J Arraras
- Oncology Departments, Complejo Hospitalario de Navarra
| | - O Morag
- Oncology, Sheba Medical Center, Tel Hashomer, Israel
| | - C Pompili
- Thoracic Surgery, Ospedali Riuniti Di Acona, Italien
| | - G Ioannidis
- Oncology Department, Nicosia General Hospital, Zypern
| | - M Georgu
- Oncology, Lincoln County Hospital
| | - C Navarra
- Psychology, Università Degli Studi Di Roma 'La Sapienza'
| | - W Chie
- Graduate Institute of Epidemiology and Preventive Medicine and Department of Public Health, College of Public Health, National Taiwan University, Taipei, Taiwan
| | - C Johnson
- Surgical Unit, University of Southampton
| | - A Himpel
- Center for Clinical Studies, University Hospital Regensburg,
| | - C Schulz
- Med. Klinik und Poliklinik II, Klinikum der Universität Regensburg,
| | - T Bohrer
- Thoraxchirurgie, Klinikum Bamberg
| | - A Janssens
- Thoracic Oncology, Universitair Ziekenhuis Antwerpen
| | - D Kulis
- European Organisation for Research and Treatment of Cancer, Quality of Life Department
| | - A Bottomley
- Quality of Life Department, Eortc Data Center Brussels
| | - M Koller
- Center for Clinical Studies, University Hospital Regensburg,
| |
Collapse
|
6
|
Brédart A, Anota A, Young T, Tomaszewski KA, Arraras JI, Moura De Albuquerque Melo H, Schmidt H, Friend E, Bergenmar M, Costantini A, Vassiliou V, Hureaux J, Marchal F, Tomaszewska IM, Chie WC, Ramage J, Beaudeau A, Conroy T, Bleiker E, Kulis D, Bonnetain F, Aaronson NK. Phase III study of the European Organisation for Research and Treatment of Cancer satisfaction with cancer care core questionnaire (EORTC PATSAT-C33) and specific complementary outpatient module (EORTC OUT-PATSAT7). Eur J Cancer Care (Engl) 2017; 27. [PMID: 29094784 DOI: 10.1111/ecc.12786] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/20/2017] [Indexed: 11/27/2022]
Abstract
Advances in cancer care delivery require revision and further development of questionnaires assessing patients' perceived quality of care. This study pre-tested the revised EORTC satisfaction with cancer care core questionnaire applicable in both the cancer inpatient and outpatient settings, and its new, outpatient-specific complementary module. The process of revision, development of the extended application, and pre-testing of these questionnaires was based on phases I to III of the "EORTC Quality of Life Group Module Development Guidelines." In phase III, patients in 11 countries in four European regions, South America and Asia completed provisional versions of the questionnaires. Fifty-seven relevant issues selected from literature reviews and input from experts were operationalized into provisional items, and subsequently translated into ten languages. Assessment of understanding, acceptability, redundancy and relevance by patients (n = 151) from oncology inpatient wards, and outpatient chemotherapy, radiotherapy and consultation settings, led to retention of, deletion of and merging of 40, 14 and 6 items respectively. Cronbach's alpha coefficients for hypothesized questionnaire scales were above 0.80. Our results provide preliminary support for the 33-item EORTC Satisfaction with cancer care core questionnaire and the 7-item complementary module specific for the outpatient care setting. A large scale phase IV cross-cultural psychometric study is now underway.
Collapse
Affiliation(s)
- A Brédart
- Institut Curie, Psycho-Oncology Unit, Paris, France.,University Paris Descartes, Boulogne Billancourt, France.,Quality of Life and Cancer Clinical Research Platform, CHU Besançon, France
| | - A Anota
- Methodology and Quality of Life in Oncology unit (INSERM UMR 1098), Quality of Life and Cancer Clinical Research Platform, CHU Besançon, France
| | - T Young
- Lynda Jackson Macmillan Centre, East& North Hertfordshire NHS Trust including Mount Vernon Cancer Centre, London, UK
| | - K A Tomaszewski
- Health Outcomes Research Unit, Department of Gerontology, Geriatrics and Social Work, Faculty of Education, Ignatianum Academy, Krakow, Poland
| | - J I Arraras
- Departments of Oncology, Complejo Hospitalario of Navarre, Pamplona, Spain
| | | | - H Schmidt
- Institute for Health and Nursing Science, Martin Luther University Halle-Wittenberg, Germany
| | - E Friend
- Basingstoke & North Hampshire Hospital, Basingstoke, UK
| | - M Bergenmar
- Department of Oncology-Pathology, Karolinska Institutet, Center for Digestive Diseases, Karolinska University Hospital, Stockholm, Sweden
| | - A Costantini
- Faculty of Medicine and Psychology, Psychoncology Unit, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy
| | - V Vassiliou
- Bank of Cyprus Oncology Centre, Nicosia, Cyprus
| | - J Hureaux
- CHU Angers, Pulmonology Department and Angers University, Angers, France
| | - F Marchal
- Institut de Cancérologie de Lorraine, Surgery Department, CRAN, UMR 7039, Université de Lorraine, CNRS, Vandoeuvre-lès-Nancy, France
| | - I M Tomaszewska
- Department of Medical Education, Jagiellonian University Medical College, Krakow, Poland
| | - W-C Chie
- Institute of Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan
| | - J Ramage
- Basingstoke & North Hampshire Hospital, Basingstoke, UK
| | - A Beaudeau
- Institut Curie, Psycho-Oncology Unit, Paris, France.,University Paris Descartes, Boulogne Billancourt, France.,Quality of Life and Cancer Clinical Research Platform, CHU Besançon, France
| | - T Conroy
- Institut de Cancérologie de Lorraine, Medical Oncology Department and EA 4360, Lorraine University, Vandoeuvre-lès-Nancy, France
| | - E Bleiker
- Division of Psychosocial Research & Epidemiology, the Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - D Kulis
- EORTC Quality of Life Department, Brussels, Belgium
| | - F Bonnetain
- Methodology and Quality of Life in Oncology unit (INSERM UMR 1098), Quality of Life and Cancer Clinical Research Platform, CHU Besançon, France
| | - N K Aaronson
- Division of Psychosocial Research & Epidemiology, the Netherlands Cancer Institute, Amsterdam, The Netherlands
| | | |
Collapse
|
7
|
Koller M, Hjermstad MJ, Tomaszewski KA, Tomaszewska IM, Hornslien K, Harle A, Arraras JI, Morag O, Pompili C, Ioannidis G, Georgiou M, Navarra C, Chie WC, Johnson CD, Himpel A, Schulz C, Bohrer T, Janssens A, Kuliś D, Bottomley A. An international study to revise the EORTC questionnaire for assessing quality of life in lung cancer patients. Ann Oncol 2017; 28:2874-2881. [PMID: 28945875 DOI: 10.1093/annonc/mdx453] [Citation(s) in RCA: 36] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
BACKGROUND The European Organization for Research and Treatment of Cancer (EORTC) QLQ-LC13 was the first module to be used in conjunction with the core questionnaire, the QLQ-C30. Since the publication of the LC13 in 1994, major advances have occurred in the treatment of lung cancer. Given this, an update of the EORTC QLQ-LC13 was undertaken. METHODS The study followed phases I to III of the EORTC Module Development Guidelines. Phase I generated relevant quality-of-life issues using a mix of sources including the involvement of 108 lung cancer patients. Phase II transformed issues into questionnaire items. In an international multicenter study (phase III), patients completed both the EORTC QLQ-C30 and the 48-item provisional lung cancer module generated in phases I and II. Patients rated each of the items regarding relevance, comprehensibility, and acceptance. Patient ratings were assessed against a set of prespecified statistical criteria. Descriptive statistics and basic psychometric analyses were carried out. RESULTS The phase III study enrolled 200 patients with histologically confirmed lung cancer from 12 centers in nine countries (Cyprus, Germany, Italy, Israel, Spain, Norway, Poland, Taiwan, and the UK). Mean age was 64 years (39 - 91), 59% of the patients were male, 82% had non-small-cell lung cancer, and 56% were treated with palliative intent. Twenty-nine of the 48 questions met the criteria for inclusion. CONCLUSIONS The resulting module with 29 questions, thus currently named EORTC QLQ-LC29, retained 12 of the 13 original items, supplemented with 17 items that primarily assess treatment side-effects of traditional and newer therapies.
Collapse
Affiliation(s)
- M Koller
- Center for Clinical Studies, University Hospital Regensburg, Regensburg, Germany.
| | - M J Hjermstad
- Regional Advisory Unit for Palliative Care, Department of Oncology, Oslo University Hospital, Oslo, and European Palliative Care Research Center (PRC), Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, NTNU, Norwegian University of Science and Technology and St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway
| | - K A Tomaszewski
- Health Outcomes Research Unit, Faculty of Education, Ignatianum Academy, Krakow, Poland
| | - I M Tomaszewska
- Department of Medical Education, Jagiellonian University Medical College, Krakow, Poland
| | - K Hornslien
- Department of Oncology, Oslo University Hospital, Oslo, Norway
| | - A Harle
- Poole Hospital NHS Foundation Trust, and The Christie NHS Foundation Trust, Manchester, UK
| | - J I Arraras
- Oncology Departments, Complejo Hospitalario de Navarra, Pamplona, Spain
| | - O Morag
- Chaim Sheba Medical Center, Ramat-Gan, Israel
| | - C Pompili
- St.James's University Hospital, Leeds, UK
| | - G Ioannidis
- Oncology Department, Nicosia General Hospital Cyprus, Nicosia, Cyprus
| | - M Georgiou
- Bank of Cyprus Oncology Center, Nicosia, Cyprus
| | - C Navarra
- Azienda Ospedaliera Sant'Andrea, Rome, Italy
| | - W-C Chie
- Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei; Department of Public Health, College of Public Health, National Taiwan University, Taipei, Republic of Taiwan
| | - C D Johnson
- Surgical Unit, University of Southampton, Southampton, UK
| | - A Himpel
- Center for Clinical Studies, University Hospital Regensburg, Regensburg, Germany
| | - C Schulz
- Department of Internal Medicine, University Hospital Regensburg, Regensburg
| | - T Bohrer
- Department of Thoracic Surgery, Bamberg, Germany
| | - A Janssens
- Thoracic Oncology, MOCA, Antwerp University Hospital, Edegem
| | - D Kuliś
- Quality of Life Department, EORTC, Brussels, Belgium
| | - A Bottomley
- Quality of Life Department, EORTC, Brussels, Belgium
| |
Collapse
|
8
|
Vivat B, Young TE, Winstanley J, Arraras JI, Black K, Boyle F, Bredart A, Costantini A, Guo J, Irarrazaval ME, Kobayashi K, Kruizinga R, Navarro M, Omidvari S, Rohde GE, Serpentini S, Spry N, Van Laarhoven HWM, Yang GM. The international phase 4 validation study of the EORTC QLQ-SWB32: A stand-alone measure of spiritual well-being for people receiving palliative care for cancer. Eur J Cancer Care (Engl) 2017; 26. [PMID: 28776784 DOI: 10.1111/ecc.12697] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/27/2017] [Indexed: 12/18/2022]
Abstract
The EORTC Quality of Life Group has just completed the final phase (field-testing and validation) of an international project to develop a stand-alone measure of spiritual well-being (SWB) for palliative cancer patients. Participants (n = 451)-from 14 countries on four continents; 54% female; 188 Christian; 50 Muslim; 156 with no religion-completed a provisional 36-item measure of SWB plus the EORTC QLQ-C15-PAL (PAL), then took part in a structured debriefing interview. All items showed good score distribution across response categories. We assessed scale structure using principal component analysis and Rasch analysis, and explored construct validity, and convergent/divergent validity with the PAL. Twenty-two items in four scoring scales (Relationship with Self, Relationships with Others, Relationship with Someone or Something Greater, and Existential) explained 53% of the variance. The measure also includes a global SWB item and nine other items. Scores on the PAL global quality-of-life item and Emotional Functioning scale weakly-moderately correlated with scores on the global SWB item and two of the four SWB scales. This new validated 32-item SWB measure addresses a distinct aspect of quality-of-life, and is now available for use in research and clinical practice, with a role as both a measurement and an intervention tool.
Collapse
Affiliation(s)
- B Vivat
- Marie Curie Palliative Care Research Department, Division of Psychiatry, Faculty of Medical Sciences, University College London, London, UK
| | - T E Young
- Supportive Oncology Research Team, East & North Hertfordshire NHS Trust including Mount Vernon Cancer Centre, Northwood, Middlesex, UK
| | - J Winstanley
- Patricia Ritchie Centre for Cancer Care, University of Sydney, North Sydney, NSW, Australia
| | - J I Arraras
- Department of Oncology, Complejo Hospitalario de Navarra, Pamplona, Spain
| | - K Black
- St Gemma's Hospice, Leeds, UK
| | - F Boyle
- Patricia Ritchie Centre for Cancer Care, University of Sydney, North Sydney, NSW, Australia
| | - A Bredart
- Psycho-Oncology Unit, Institut Curie, Paris, France
| | - A Costantini
- Sant'Andrea Hospital Faculty of Medicine and Psychology, Sapienza University of Rome, Rome, Italy
| | - J Guo
- Palliative Ward, Shengjing Hospital, China Medical University, Shenyang, Liaoning, China
| | | | - K Kobayashi
- Department of Respiratory Medicine, Saitama Medical University International Medical Centre, Saitama, Japan
| | - R Kruizinga
- Medical Oncology Academic Medical Centre, Amsterdam, The Netherlands
| | - M Navarro
- Coordinadora del Centro de Apoyo para la Atención Integral, Division de Investigación Clínica, Instituto Nacional de Cancerologia, Mexico DF, Mexico
| | - S Omidvari
- Health Metrics Research Centre, Iranian Institute for Health Sciences Research, ACECR, Tehran, Iran
| | - G E Rohde
- Faculty of Health & Sport Sciences, University of Agder & Sorlandet Hospital, Kristiansand, Norway
| | - S Serpentini
- Unit of Psychoncology, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy
| | - N Spry
- Oncology Department, Faculty of Medicine Dentistry and Health Sciences, University of Western Australia, Crawley, WA, Australia
| | | | - G M Yang
- National Cancer Centre Singapore 2, Lien Centre for Palliative Care, Singapore
| | | |
Collapse
|
9
|
Arraras JI, Illarramendi JJ, de la Cruz S, Asin G, Manterola A, Ibanez B, Salgado E, Cambra K, Zarandona U, Dominguez MA, Vera R. Erratum:Quality of life in long-term premenopausal early-stage breast cancer survivors from Spain. Effects of surgery and time since surgery. J BUON 2016; 21:1573. [PMID: 28039732] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
In this article published in Volume 21, issue 5, the authors' names were incorrectly stated in the Pubmed abstract as: "Ignacio Arraras J(1), Juan Illarramendi J, de la Cruz S, Asin G, Manterola A, Ibanez B, Salgado E, Cambra K, Zarandona U, Angel Dominguez M, Vera R.". The correct authors' names are: "Arraras JI(1), Illarramendi JJ, de la Cruz S, Asin G, Manterola A, Ibanez B, Salgado E, Cambra K, Zarandona U, Dominguez MA, Vera R.". This error appeared only in the PubMed database and not in the print form of the Journal.
Collapse
Affiliation(s)
- J I Arraras
- Complejo Hospitalario de Navarra, Department of Medical Oncology, Pamplona, Spain
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Vivat B, Young T, Winstanley J, Arraras JI, Bennett MI, Brédart A, Costantini A, Fisher SE, Greimel E, Guo J, Irarrazaval ME, Kobayashi K, Kruizinga R, Navarro M, Omidvari S, Rohde GE, Serpentini S, van Laarhoven HWM, Yang G. DEVELOPMENT AND VALIDATION OF A CROSS-CULTURAL EORTC MEASURE OF SPIRITUAL WELLBEING (SWB) FOR PALLIATIVE CARE PATIENTS WITH CANCER. BMJ Support Palliat Care 2014. [DOI: 10.1136/bmjspcare-2014-000653.14] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
11
|
Arraras JI, Villafranca E, Arias de la Vega F, Romero P, Rico M, Vila M, Asín G, Chicata V, Domínguez MA, Lainez N, Manterola A, Martínez E, Martínez M. The EORTC Quality of Life Questionnaire for patients with prostate cancer: EORTC QLQ-PR25. Validation study for Spanish patients. Clin Transl Oncol 2009; 11:160-4. [PMID: 19293053 DOI: 10.1007/s12094-009-0332-z] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
OBJECTIVES The EORTC Quality of Life (QL) Group has developed a questionnaire, the EORTC QLQ-PR25, for evaluating QL in prostate cancer. The aim of this study is to assess the psychometric properties of the EORTC QLQPR25 when applied to a sample of Spanish patients. MATERIALS AND METHODS One hundred and thirty-seven prostate cancer patients with localised disease who started radiotherapy with radical intention combined with or without hormonotherapy prospectively completed the EORTC QLQ-C30 and EORTC QLQ-PR25 questionnaires three times: on the first and last day of radiotherapy and in the follow-up period. Psychometric evaluation of the questionnaires' structure, reliability and validity was conducted. RESULTS Multitrait scaling analysis showed that many of the item-scale correlation coefficients met the standards of convergent and discriminant validity. Exceptions appeared mainly in the scales for bowel symptoms and for hormonal- treatment-related symptoms. Cronbach's coefficients of the scales were good (0.72-0.86) for the urinary symptoms and sexual function scales but they were lower (<0.70) for the bowel and hormonal treatment scales. Most scales of the EORTC QLQ-PR25 had low to moderate intercorrelations. Correlations between the scales of the QLQ-C30 and the module were generally low. Group comparison analyses showed better QL in patients with higher Performance Status. Changes in QL appeared throughout the measurements. These were in line with the treatment process. CONCLUSIONS The EORTC QLQ-PR25 was a reliable and valid instrument when applied to a sample of Spanish prostate cancer patients. These results are in line with those of the EORTC validation study.
Collapse
Affiliation(s)
- J I Arraras
- Radiotherapeutic Oncology Department, Hospital of Navarre, Pamplona, Navarra, Spain.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Brédart A, Coens C, Aaronson N, Chie WC, Efficace F, Conroy T, Blazeby JM, Hammerlid E, Costantini M, Joly F, Schraub S, Sezer O, Arraras JI, Rodary C, Costantini A, Mehlitz M, Razavi D, Bottomley A. Determinants of patient satisfaction in oncology settings from European and Asian countries: Preliminary results based on the EORTC IN-PATSAT32 questionnaire. Eur J Cancer 2007; 43:323-30. [PMID: 17156997 DOI: 10.1016/j.ejca.2006.10.016] [Citation(s) in RCA: 53] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2006] [Accepted: 10/06/2006] [Indexed: 11/12/2022]
Abstract
The aim of this study was to identify factors associated significantly with hospitalised cancer patients' satisfaction with care. Patients were recruited from four geographical/cultural groups, including five European countries and Taiwan. They rated their level of satisfaction by completing the EORTC IN-PATSAT32 questionnaire at home. Additionally, data were collected on the sociodemographic and clinical characteristics and the quality of life of the patients, as well as on institutional characteristics. Of 762 patients recruited, 647 (85%) returned a completed questionnaire. The number of nurses and doctors per bed, institution size, geo-cultural origin, ward setting, teaching/non-teaching setting, treatment toxicity, global health status, participation in clinical trials and education level were all associated significantly at the multivariate level with satisfaction with doctor and nurse interpersonal skills, information provision, availability, and/or overall satisfaction. A number of patient-, institutional- and culture-related factors are associated with the perceived quality of cancer care. Future studies, with appropriate sampling frames and stratification procedures, are needed to better understand cross-national and cross-cultural differences in cancer patient satisfaction.
Collapse
Affiliation(s)
- A Brédart
- Institut Curie, Psycho-Oncology Unit, 26, rue d'Ulm, FR 75005 PARIS CEDEX 05, Paris, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Arias F, Dominguez M, Villafranca E, Manterola A, Romero P, Martinez E, Oria E, Arraras J, Atienza P, Garcia-Bragado F, Medina J. Hyperfractionated Radiation Therapy and Cisplatin for Locally Advanced Head and Neck Cancer (LAHNC): a Comparison among Two Consecutive Protocols of Treatment at a Single-Institution. Int J Radiat Oncol Biol Phys 2005. [DOI: 10.1016/j.ijrobp.2005.07.613] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
14
|
Brédart A, Bottomley A, Blazeby JM, Conroy T, Coens C, D'Haese S, Chie WC, Hammerlid E, Arraras JI, Efficace F, Rodary C, Schraub S, Costantini M, Costantini A, Joly F, Sezer O, Razavi D, Mehlitz M, Bielska-Lasota M, Aaronson NK. An international prospective study of the EORTC cancer in-patient satisfaction with care measure (EORTC IN-PATSAT32). Eur J Cancer 2005; 41:2120-31. [PMID: 16182120 DOI: 10.1016/j.ejca.2005.04.041] [Citation(s) in RCA: 156] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2005] [Accepted: 04/14/2005] [Indexed: 10/25/2022]
Abstract
Little is known about patients' satisfaction with care in oncology hospitals across cultural contexts. Within the EORTC, we developed a 32-item satisfaction with care questionnaire to measure patients' appraisal of hospital doctors and nurses, as well as aspects of care organisation and services. This study assessed the psychometric characteristics of the questionnaire, the EORTC IN-PATSAT32, in a large, international sample of patients with cancer. Patients discharged from a surgery or medical oncology ward in nine countries were invited to complete at home the EORTC IN-PATSAT32 as well as other instruments for psychometric testing. Of 762 eligible patients recruited, 15% failed to return the questionnaire. Of the 647 compliant patients, 63% completed the questionnaires within 15 min and 82% required no help in its completion. Multitrait scaling analysis revealed excellent internal consistency and convergent validity, although some scales within the IN-PATSAT32 were relatively highly correlated. Test-retest data on 113 patients showed high reliability for most scales. Scales of the IN-PATSAT32 and of the QLQ-C30 were not significantly correlated, suggesting that the two questionnaires are assessing quite distinct concepts. The scales of the IN-PATSAT32 were able to discriminate clearly between patients with differing care expectations and differing intentions to recommend their hospital to others. This study supports the acceptability to patients, and the psychometric robustness of the EORTC IN-PATSAT32 questionnaire. Further studies are needed to assess the responsiveness of the questionnaire to changes in the structure and process of care over time.
Collapse
Affiliation(s)
- A Brédart
- Institut Curie, Psycho-Oncology Unit, 26, rue d'Ulm, FR 75005 Paris cedex 05, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Brédart A, Bottomley A, Blazeby J, Conroy T, Chie WC, Hammerlid E, Arraras J, Costantini M, Schraub S, Fleissner C. An international prospective study of the psychometric properties of the EORTC Satisfaction With Care Measure (EORTC QLQ SAT-32). J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.6030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- A. Brédart
- Inst Curie, Paris, France; EORTC Data Ctr, Brussels, Belgium; Univ of Bristol, Bristol, United Kingdom; Ctr Alexis Vautrin, Vandoeuvre-les-Nancy Cedex, France; National Taiwan Univ, Taipei, Taiwan Republic of China; Sahlgrenska Hosp, Goteborg, Sweden; Hosp of Navarra, Pamplona, Spain; National Cancer Institute, Genova, Italy; Ctr Paul Strauss, Strasbourg, France; Univ Hosp Charité Berlin, Berlin, Germany
| | - A. Bottomley
- Inst Curie, Paris, France; EORTC Data Ctr, Brussels, Belgium; Univ of Bristol, Bristol, United Kingdom; Ctr Alexis Vautrin, Vandoeuvre-les-Nancy Cedex, France; National Taiwan Univ, Taipei, Taiwan Republic of China; Sahlgrenska Hosp, Goteborg, Sweden; Hosp of Navarra, Pamplona, Spain; National Cancer Institute, Genova, Italy; Ctr Paul Strauss, Strasbourg, France; Univ Hosp Charité Berlin, Berlin, Germany
| | - J. Blazeby
- Inst Curie, Paris, France; EORTC Data Ctr, Brussels, Belgium; Univ of Bristol, Bristol, United Kingdom; Ctr Alexis Vautrin, Vandoeuvre-les-Nancy Cedex, France; National Taiwan Univ, Taipei, Taiwan Republic of China; Sahlgrenska Hosp, Goteborg, Sweden; Hosp of Navarra, Pamplona, Spain; National Cancer Institute, Genova, Italy; Ctr Paul Strauss, Strasbourg, France; Univ Hosp Charité Berlin, Berlin, Germany
| | - T. Conroy
- Inst Curie, Paris, France; EORTC Data Ctr, Brussels, Belgium; Univ of Bristol, Bristol, United Kingdom; Ctr Alexis Vautrin, Vandoeuvre-les-Nancy Cedex, France; National Taiwan Univ, Taipei, Taiwan Republic of China; Sahlgrenska Hosp, Goteborg, Sweden; Hosp of Navarra, Pamplona, Spain; National Cancer Institute, Genova, Italy; Ctr Paul Strauss, Strasbourg, France; Univ Hosp Charité Berlin, Berlin, Germany
| | - W.-C. Chie
- Inst Curie, Paris, France; EORTC Data Ctr, Brussels, Belgium; Univ of Bristol, Bristol, United Kingdom; Ctr Alexis Vautrin, Vandoeuvre-les-Nancy Cedex, France; National Taiwan Univ, Taipei, Taiwan Republic of China; Sahlgrenska Hosp, Goteborg, Sweden; Hosp of Navarra, Pamplona, Spain; National Cancer Institute, Genova, Italy; Ctr Paul Strauss, Strasbourg, France; Univ Hosp Charité Berlin, Berlin, Germany
| | - E. Hammerlid
- Inst Curie, Paris, France; EORTC Data Ctr, Brussels, Belgium; Univ of Bristol, Bristol, United Kingdom; Ctr Alexis Vautrin, Vandoeuvre-les-Nancy Cedex, France; National Taiwan Univ, Taipei, Taiwan Republic of China; Sahlgrenska Hosp, Goteborg, Sweden; Hosp of Navarra, Pamplona, Spain; National Cancer Institute, Genova, Italy; Ctr Paul Strauss, Strasbourg, France; Univ Hosp Charité Berlin, Berlin, Germany
| | - J. Arraras
- Inst Curie, Paris, France; EORTC Data Ctr, Brussels, Belgium; Univ of Bristol, Bristol, United Kingdom; Ctr Alexis Vautrin, Vandoeuvre-les-Nancy Cedex, France; National Taiwan Univ, Taipei, Taiwan Republic of China; Sahlgrenska Hosp, Goteborg, Sweden; Hosp of Navarra, Pamplona, Spain; National Cancer Institute, Genova, Italy; Ctr Paul Strauss, Strasbourg, France; Univ Hosp Charité Berlin, Berlin, Germany
| | - M. Costantini
- Inst Curie, Paris, France; EORTC Data Ctr, Brussels, Belgium; Univ of Bristol, Bristol, United Kingdom; Ctr Alexis Vautrin, Vandoeuvre-les-Nancy Cedex, France; National Taiwan Univ, Taipei, Taiwan Republic of China; Sahlgrenska Hosp, Goteborg, Sweden; Hosp of Navarra, Pamplona, Spain; National Cancer Institute, Genova, Italy; Ctr Paul Strauss, Strasbourg, France; Univ Hosp Charité Berlin, Berlin, Germany
| | - S. Schraub
- Inst Curie, Paris, France; EORTC Data Ctr, Brussels, Belgium; Univ of Bristol, Bristol, United Kingdom; Ctr Alexis Vautrin, Vandoeuvre-les-Nancy Cedex, France; National Taiwan Univ, Taipei, Taiwan Republic of China; Sahlgrenska Hosp, Goteborg, Sweden; Hosp of Navarra, Pamplona, Spain; National Cancer Institute, Genova, Italy; Ctr Paul Strauss, Strasbourg, France; Univ Hosp Charité Berlin, Berlin, Germany
| | - C. Fleissner
- Inst Curie, Paris, France; EORTC Data Ctr, Brussels, Belgium; Univ of Bristol, Bristol, United Kingdom; Ctr Alexis Vautrin, Vandoeuvre-les-Nancy Cedex, France; National Taiwan Univ, Taipei, Taiwan Republic of China; Sahlgrenska Hosp, Goteborg, Sweden; Hosp of Navarra, Pamplona, Spain; National Cancer Institute, Genova, Italy; Ctr Paul Strauss, Strasbourg, France; Univ Hosp Charité Berlin, Berlin, Germany
| |
Collapse
|
16
|
Bjorner JB, Petersen MA, Groenvold M, Aaronson N, Ahlner-Elmqvist M, Arraras JI, Brédart A, Fayers P, Jordhoy M, Sprangers M, Watson M, Young T. Use of item response theory to develop a shortened version of the EORTC QLQ-C30 emotional functioning scale. Qual Life Res 2004; 13:1683-97. [PMID: 15651539 DOI: 10.1007/s11136-004-7866-x] [Citation(s) in RCA: 45] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
BACKGROUND As part of a larger study whose objective is to develop an abbreviated version of the EORTC QLQ-C30 suitable for research in palliative care, analyses were conducted to determine the feasibility of generating a shorter version of the 4-item emotional functioning (EF) scale that could be scored in the original metric. METHODS We used data from 24 European cancer studies conducted in 10 different languages (n = 8242). Item selection was based on analyses by item response theory (IRT). Based on the IRT results, a simple scoring algorithm was developed to predict the original 4-item EF sum scale score from a reduced number of items. RESULTS Both a 3-item and a 2-item version (item 21 'Did you feel tense?' and item 24 'Did you feel depressed?') predicted the total score with excellent agreement and very little bias. In group comparisons, the 2-item scale led to the same conclusions as those based on the original 4-item scale with little or no loss of measurement efficiency. CONCLUSION Although these results are promising, confirmatory studies are needed based on independent samples. If such additional studies yield comparable results, incorporation of the 2-item EF scale in an abbreviated version of the QLQ-C30 for use in palliative care research settings would be justified. The analyses reported here demonstrate the usefulness of the IRT-based methodology for shortening questionnaire scales.
Collapse
Affiliation(s)
- J B Bjorner
- Quality Metric Incorporated, Lincoln, RI 02865, USA.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Blazeby JM, Conroy T, Bottomley A, Vickery C, Arraras J, Sezer O, Moore J, Koller M, Turhal NS, Stuart R, Van Cutsem E, D'haese S, Coens C. Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-STO 22, to assess quality of life in patients with gastric cancer. Eur J Cancer 2004; 40:2260-8. [PMID: 15454251 DOI: 10.1016/j.ejca.2004.05.023] [Citation(s) in RCA: 149] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2004] [Accepted: 05/20/2004] [Indexed: 12/14/2022]
Abstract
The purpose of this study was to define the measurement properties and clinical validity of the European Organisation for Research and Treatment of Cancer (EORTC) questionnaire module to assess health-related quality of life (HRQL) in gastric cancer. The EORTC gastric cancer module, QLQ-STO 22, was administered with the QLQ-C30, core questionnaire, to 219 patients undergoing treatment with curative or palliative intent before and after treatment. Reliability and validity of the module was tested and patients' debriefing comments analysed. Compliance rates were high, questionnaires well accepted and less than 4% of items had missing data. Multi-trait scaling analyses and face validity refined the module to five scales and four single items. Scales distinguished between clinically distinct groups of patients and demonstrated treatment-induced changes over time. Test-retest scores demonstrated good reliability. The EORTC QLQ-STO 22 demonstrates psychometric and clinical validity that supports its use to supplement the EORTC QLQ-C30 to assess quality of life in patients with gastric cancer undergoing surgery, surgery and chemoradiotherapy, palliative chemotherapy, palliative surgery and best supportive care.
Collapse
Affiliation(s)
- J M Blazeby
- Clinical Sciences at South Bristol and Department of Social Medicine, Bristol Royal Infirmary, University of Bristol, Bristol, UK.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Blazeby JM, Conroy T, Hammerlid E, Fayers P, Sezer O, Koller M, Arraras J, Bottomley A, Vickery CW, Etienne PL, Alderson D. Clinical and psychometric validation of an EORTC questionnaire module, the EORTC QLQ-OES18, to assess quality of life in patients with oesophageal cancer. Eur J Cancer 2003; 39:1384-94. [PMID: 12826041 DOI: 10.1016/s0959-8049(03)00270-3] [Citation(s) in RCA: 287] [Impact Index Per Article: 13.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
Quality of life (QOL) assessment requires clinically relevant questionnaires that yield accurate data. This study defined measurement properties and the clinical validity of the European Organisation for Research and Treatment of Cancer (EORTC) questionnaire module to assess QOL in oesophageal cancer. The oesophageal module the QLQ-OES24 and core questionnaire, the Quality of Life-Core 30 questionnaire (QLQ-C30) was administered patients undergoing treatment with curative (n=267) or palliative intent (n=224) and second assessments performed 3 months or 3 weeks later respectively. Psychometric tests examined scales and measurement properties of the module. Questionnaires were well accepted, compliance rates were high and less than 2% of items had missing data. Multi-trait scaling analyses and face validity refined the module to four scales and six single items (QLQ-OES18). Selective scales distinguished between clinically distinct groups of patients and demonstrated treatment-induced changes over time. The EORTC QLQ-OES18 demonstrates good psychometric and clinical validity. It is recommended for use with the core questionnaire, the QLQ-C30, to assess QOL in patients with oesophageal cancer.
Collapse
Affiliation(s)
- J M Blazeby
- Department of Surgery, University of Bristol, Bristol Royal Infirmary, Bristol BS2 3HW, UK.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Greimel E, Bottomley A, Cull A, Waldenstrom AC, Arraras J, Chauvenet L, Holzner B, Kuljanic K, Lebrec J, D'haese S. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer. Eur J Cancer 2003; 39:1402-8. [PMID: 12826043 DOI: 10.1016/s0959-8049(03)00307-1] [Citation(s) in RCA: 154] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
This study defines the psychometric properties of the European Organisation for Research and Treatment of Cancer (EORTC) quality of life (QOL) questionnaire designed to measure the QOL of patients with ovarian cancer. The ovarian cancer module (EORTC QLQ-OV28) was developed to supplement the EORTC QLQ-C30. The core questionnaire and the QLQ-OV28 were prospectively administered to 368 ovarian cancer patients after they had been treated with radical or debulking surgery followed by chemotherapy. The QLQ-OV28 module assesses abdominal/gastrointestinal symptoms, peripheral neuropathy, other chemotherapy side-effects, hormonal/menopausal symptoms, body image, attitude to disease/treatment and sexual functioning. Questionnaires were well accepted by patients, baseline compliance rates were 86%, 72% provided a second assessment, less than 3% of the items had missing data. Multi-trait scaling analyses confirmed the hypothesised scales. All hypothesised scales exhibited good psychometric properties. These results support the clinical and psychometric validity of the EORTC QLQ-OV28 module as a supplement to the EORTC QLQ-C30.
Collapse
Affiliation(s)
- E Greimel
- Department of Obstetrics and Gynecology, University of Graz, Auenbruggerplatz 14, A-8036 Graz, Austria.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Arraras JI, Arias F, Tejedor M, Pruja E, Marcos M, Martínez E, Valerdi J. The EORTC QLQ-C30 (version 3.0) Quality of Life questionnaire: validation study for Spain with head and neck cancer patients. Psychooncology 2002; 11:249-56. [PMID: 12112486 DOI: 10.1002/pon.555] [Citation(s) in RCA: 76] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
The EORTC Quality of Life Study Group has developed a questionnaire for evaluating Quality of Life in international clinical trials: QLQ-C30. The purpose of the present work is to validate the third version of this questionnaire (3.0) for use in Spain. Two hundred and one head and neck cancer patients completed the QLQ-C30 at one or two time points during the treatment and follow-up periods, and a subsample completed the questionnaire on three occasions. Psychometric evaluation of the structure, reliability and validity of the questionnaire was undertaken. The data support the structure and the reliability of the scales. Validity was confirmed in three ways: the interscale correlations are statistically significant and moderate, several scales and items discriminate among groups of patients with different scores on the clinical variables, and some scales reflect significant changes during treatment and the follow-up period. The EORTC QLQ-C30 (version 3.0) is a reliable and valid questionnaire when applied to a sample of Spanish head and neck cancer patients. These results are in line with previous studies.
Collapse
Affiliation(s)
- J I Arraras
- Hospital de Navarra, Oncology Department, Navarra, Spain
| | | | | | | | | | | | | |
Collapse
|
21
|
Vickery CW, Blazeby JM, Conroy T, Arraras J, Sezer O, Koller M, Rosemeyer D, Johnson CD, Alderson D. Development of an EORTC disease-specific quality of life module for use in patients with gastric cancer. Eur J Cancer 2001; 37:966-71. [PMID: 11334720 DOI: 10.1016/s0959-8049(00)00417-2] [Citation(s) in RCA: 126] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Quality of life (QL) is an important outcome in clinical trials in oncology. There is currently no valid international QL measure for gastric cancer. This paper describes the development of a QL module for gastric cancer to supplement the European Organization for Research and Treatment of Cancer (EORTC) Quality of life (QLQ-C30) questionnaire. Phases I to III of module development were conducted in the United Kingdom, France, Germany and Spain according to EORTC QL Group guidelines. Twenty relevant QL issues were generated from the literature and interviews with health professionals (n=24) and patients (n=58). This produced a 24 item provisional module. Further testing in 115 patients resulted in the QLQ-STO22, containing 22 questions, conceptualised into five scales and four single items, related to disease symptoms, treatment side-effects and emotional issues specific to gastric cancer. The use of the QLQ-C30 supplemented by the QLQ-STO22 will provide a comprehensive QL measure for international trials in gastric cancer.
Collapse
Affiliation(s)
- C W Vickery
- University Department of Surgery, Bristol Royal Infirmary, BS2 8HW, Bristol, UK
| | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Cull A, Howat S, Greimel E, Waldenstrom AC, Arraras J, Kudelka A, Chauvenet L, Gould A. Development of a European Organization for Research and Treatment of Cancer questionnaire module to assess the quality of life of ovarian cancer patients in clinical trials: a progress report. Eur J Cancer 2001; 37:47-53. [PMID: 11165129 DOI: 10.1016/s0959-8049(00)00369-5] [Citation(s) in RCA: 74] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
A questionnaire was developed, according to the European Organization for Research and Treatment of Cancer (EORTC) published guidelines, to supplement the EORTC quality of life questionnaire-core 30 (QLQ-C30) to assess the quality of life (QL) of women with ovarian cancer treated in clinical trials. The provisional 28-item module, OV28, assesses abdominal symptoms; peripheral neuropathy; other chemotherapy side-effects; hormonal symptoms; body image; attitude to disease and treatment; and sexual functioning. The first 24 items of the module (excluding sexual functioning) were included in a UK multicentre trial (SCOTROC). The trial data were used for preliminary scaling analysis. Two problematic items were identified. When these were treated as single items along with the 'other chemotherapy side-effects' the instrument showed excellent scale properties. Mean scale scores discriminated between trial patients pre- and on chemotherapy. This is a promising tool for assessing the QL of women with ovarian cancer. The EORTC international field study (Protocol 15982) to assess more fully the psychometric properties of the OV28 is well underway.
Collapse
Affiliation(s)
- A Cull
- Imperial Cancer Research Fund Psychology Research Group, Western General Hospital, Crewe Road, EH4 2XU, Edinburgh, Scotland, UK.
| | | | | | | | | | | | | | | |
Collapse
|
23
|
Sprangers MA, Groenvold M, Arraras JI, Franklin J, te Velde A, Muller M, Franzini L, Williams A, de Haes HC, Hopwood P, Cull A, Aaronson NK. The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. J Clin Oncol 1996; 14:2756-68. [PMID: 8874337 DOI: 10.1200/jco.1996.14.10.2756] [Citation(s) in RCA: 787] [Impact Index Per Article: 28.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023] Open
Abstract
PURPOSE To construct a breast cancer-specific quality-of-life questionnaire (QLQ) module to be used in conjunction with the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 and to test its reliability and validity cross-culturally. PATIENTS AND METHODS Module construction took place after the EORTC guidelines for module development. The module--the QLQ-BR23--consists of 23 items covering symptoms and side effects related to different treatment modalities, body image, sexuality, and future perspective. This module was tested in 170 Dutch, 168 Spanish, and 158 American cancer patients at two points in time. The timing for the Dutch and Spanish patients was before and during treatment with radiotherapy or chemotherapy. For the American patients, the questionnaire was administered at admission at the breast clinic and 3 months after the first assessment. RESULTS Multitrait scaling analysis confirmed the hypothesized structure of four of the five scales. Cronbach's alpha coefficients were, in general, lowest in Spain (range; .46 to .94) and highest in the United States (range; .70 to .91). On the basis of known-groups comparisons, selective scales distinguished clearly between patients differing in disease stage, previous surgery, performance status, and treatment modality, according to expectation. Additionally, selective scales detected change over time as a function of changes in performance status and treatment-induced change. CONCLUSION These results lend support to the clinical and cross-cultural validity of the QLQ-BR23 as a supplementary questionnaire for assessing specific quality-of-life issues relevant to patients with breast cancer.
Collapse
Affiliation(s)
- M A Sprangers
- Netherlands Cancer Institute, Amsterdam, The Netherlands.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Blazeby JM, Alderson D, Winstone K, Steyn R, Hammerlid E, Arraras J, Farndon JR. Development of an EORTC questionnaire module to be used in quality of life assessment for patients with oesophageal cancer. The EORTC Quality of Life Study Group. Eur J Cancer 1996; 32A:1912-7. [PMID: 8943674 DOI: 10.1016/0959-8049(96)00199-2] [Citation(s) in RCA: 139] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Quality of life (QOL) assessments in patients with oesophageal cancer should provide clinically meaningful data that can assist management decision making. This study describes the development of a specific module for oesophageal cancer to use with the European Organisation into Research and Treatment of Cancer (EORTC) QOL questionnaire, the EORTC QLQ-C30. Relevant QOL issues were generated from a literature search and interviews with patients and oesophageal cancer specialists. Issues were formulated into items compatible with those of the EORTC QLQ-C30. The provisional module was pretested in patients from the United Kingdom, Spain and Sweden. The resulting module, the QLQ-OES 24, includes 24 items conceptualised as containing six scales and five single items. The addition of an oesophageal cancer-specific module to the core questionnaire should improve the sensitivity and specificity of the core instrument to allow detection of even small benefits accrued from new treatment modalities.
Collapse
Affiliation(s)
- J M Blazeby
- University Department of Surgery, Bristol Royal Infirmary, U.K
| | | | | | | | | | | | | |
Collapse
|